Contributions
Abstract: PB2234
Type: Publication Only
Background
The combination of pomalidomide and low-dose dexamethasone has proved to be effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome. MM remains an incurable disease with unavoidable relapses. However, with the new therapeutic approaches available to date, prolonged survival of patients has been demostrated. Pomalidomide is a distinct immunomodulatory drug with potent antimyeloma activity, and has demonstrated efficacy even in patients that are refractory to Lenalidomide. In order to increase response rate, commonly it is used in combination.
Aims
We analize retrospectively, in a real-worl clinical practice setting, the efficacy, and safety of a pomalidomide-based regimens in patients with RRMM, treated in 3 centers. We evaluated the efficacy either when given with dexamethasone in 23 patients or in combination with oral cyclophsphamide +/- claritromycin in 25 patients. We evaluated the impact of adverse prognostic factors of cytogenetics and refractoriness to previous lenalidomide.
Methods
This multicenter estudy included fourty eight patients treated with Pomalidomide-based regimen for RRMM, between 2013-2017.
Results
Conclusion
Pomalidomide-based treatment is effective, even in heavily treated RRMM, and adverse citogenetic group. In our study there was no benefit from using pomalidomide in combination with oral cyclophosphamide +/- claritromycin, but this should be confirmed in further studies. Lenalidomide refractory patients had shorter progressión free survival.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Myeloma, Relapse, Treatment
Abstract: PB2234
Type: Publication Only
Background
The combination of pomalidomide and low-dose dexamethasone has proved to be effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome. MM remains an incurable disease with unavoidable relapses. However, with the new therapeutic approaches available to date, prolonged survival of patients has been demostrated. Pomalidomide is a distinct immunomodulatory drug with potent antimyeloma activity, and has demonstrated efficacy even in patients that are refractory to Lenalidomide. In order to increase response rate, commonly it is used in combination.
Aims
We analize retrospectively, in a real-worl clinical practice setting, the efficacy, and safety of a pomalidomide-based regimens in patients with RRMM, treated in 3 centers. We evaluated the efficacy either when given with dexamethasone in 23 patients or in combination with oral cyclophsphamide +/- claritromycin in 25 patients. We evaluated the impact of adverse prognostic factors of cytogenetics and refractoriness to previous lenalidomide.
Methods
This multicenter estudy included fourty eight patients treated with Pomalidomide-based regimen for RRMM, between 2013-2017.
Results
Conclusion
Pomalidomide-based treatment is effective, even in heavily treated RRMM, and adverse citogenetic group. In our study there was no benefit from using pomalidomide in combination with oral cyclophosphamide +/- claritromycin, but this should be confirmed in further studies. Lenalidomide refractory patients had shorter progressión free survival.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Myeloma, Relapse, Treatment